CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY

Trials shown by sponsor

Public title	Date of Registration	State
Recombinant IFN alpha-2b for relapsing –remitting multiple sclerosis.	2009-02-11	Registered
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 6-10-14 weeks.	2011-04-27	Registered
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months.	2011-04-29	Registered
Quimi-Hib® and Quimi-Hib(AlPO4) vaccines in an accelerated 6-10-14 weeks primary vaccination series	2012-09-12	Registered
Phase II clinical trial for the evaluation of the therapeutic vaccine candidate Terap C.	2009-02-11	Registered
Phase I/II clinical trial for the evaluation of vaccine candidate CIGB-230 in patients with chronic renal insufficiency.	2010-09-27	Registered
Phase I with CIGB-814 in rheumatoid arthritis patients	16/02/2017	Registered
Phase I clinical trial for the evaluation of the therapeutic vaccine candidate Terap C.	2010-06-11	Registered
Pharmacokinetics of the Intralesional administration of rhEGF (doses: 75 µg and 225 µg) in advance Diabetic Foot Ulcers	2013-02-08	Registered
Pharmacokinetics of intralesional EGF in patients with diabetic foot ulcers.	2010-12-24	Registered
Pharmacodynamics of the Nasalferon in healthy volunteers.	03/05/2020	Registered
OLIVO Study	01/10/2020	Registered
NEUVITAL V Study	2011-04-30	Registered
NASVAC therapeutic vaccine study	2011-05-16	Registered
NASVAC Phase II Trial in patients with Chronic Hepatitis B Virus infection	2012-10-12	Registered
Nasalferon in COVID-19	12/11/2021	Registered
Nasalferon in ARI	29/07/2022	Registered
Nasal recombinant human interferon alfa-2b in ARI	06/12/2022	Registered
MEÑIQUE Study	03/09/2021	Registered
MAMBISA Study	26/11/2020	Registered outdated

Registered Trials

Registration process

CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY

About the RPCEC

Useful resources